In the News: Lipokinetix and Hepatitis
March 1, 2002
In the News: Lipokinetix and Hepatitis
The Food and Drug Administration (FDA) is urging consumers to discontinue use of the dietary supplement Lipokinetix®, which has been associated with multiple reports of hepatitis and hepatic failure.
Marketed by Syntrax Innovations, Inc. for weight loss, Lipokinetix contains phenylpropanolamine (norephedrine), caffeine, yohimbine (Pausinystalia johimbe), diiodothyronine, and sodium usniate. The injuries reported to the FDA occurred in persons ages 20-32 years; liver injury developed after 2-12 weeks of Lipokinetix use. No other apparent causes of liver injury were identified in these reports.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content